个体化指导年轻急性髓系白血病患者异基因干细胞移植
研究基于ALFA-0702试验中656例60岁以下AML患者,评估知识库算法在首次完全缓解期指导移植决策的表现。KB对总生存的预测优于ELN 2017风险分层,整合KB评分、ELN 2017和NPM1 MRD可将545例CR1患者分为移植候选者和仅化疗候选者,两组移植获益相反。
要点
- KB预测OS的C指数为68.9,优于ELN 2017的63.0。
- ELN 2017预后良好或NPM1 MRD阴性者,CR1期移植有害。
- 整合KB评分、ELN 2017和MRD可区分移植获益人群。
核心结论
- 整合KB预测、ELN 2017和MRD可能优化年轻AML患者移植时机。
研究设计与样本
- 基于ALFA-0702试验(NCT00932412)656例60岁以下AML患者的多阶段模型评估。
主要发现
- KB预测OS的C指数68.9,优于ELN 2017的63.0。
- ELN 2017预后良好者CR1期移植有害(交互检验P=.01)。
- NPM1 MRD阴性者CR1期移植有害(交互检验P=.02)。
- KB评分≥40者CR1期移植有害(交互检验P=.01)。
- 545例CR1患者中278例(51.0%)为移植候选者,267例(49.0%)为仅化疗候选者;移植候选者移植显著改善OS,仅化疗候选者移植显著缩短OS。
关键数值与推荐
- KB预测OS的C指数68.9 vs ELN 2017的63.0。
- ELN 2017预后良好与移植交互检验P=.01。
- NPM1 MRD阴性与移植交互检验P=.02。
- KB评分≥40与移植交互检验P=.01。
- 545例CR1患者中278例(51.0%)为移植候选者,267例(49.0%)为仅化疗候选者。
临床怎么用
- 可结合KB评分、ELN 2017和NPM1 MRD筛选CR1期移植获益的年轻AML患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A multistage model instructed by a large dataset (knowledge bank [KB] algorithm) has recently been developed to improve outcome predictions and tailor therapeutic decisions, including hematopoietic stem cell transplantation (HSCT) in acute myeloid leukemia (AML). We assessed the performance of the KB in guiding HSCT decisions in first complete remission (CR1) in 656 AML patients younger than 60 years from the ALFA-0702 trial (NCT00932412). KB predictions of overall survival (OS) were superior to those of European LeukemiaNet (ELN) 2017 risk stratification (C-index, 68.9 vs 63.0). Among patients reaching CR1, HSCT in CR1, as a time-dependent covariate, was detrimental in those with favorable ELN 2017 risk and those with negative NPM1 minimal residual disease (MRD; interaction tests, P = .01 and P = .02, respectively). Using KB simulations of survival at 5 years in a scenario without HSCT in CR1 (KB score), we identified, in a similar time-dependent analysis, a significant interaction between KB score and HSCT, with HSCT in CR1 being detrimental only in patients with a good prognosis based on KB simulations (KB score ≥40; interaction test, P = .01). We could finally integrate ELN 2017, NPM1 MRD, and KB scores to sort 545 CR1 patients into 278 (51.0%) HSCT candidates and 267 (49.0%) chemotherapy-only candidates. In both time-dependent and 6-month landmark analyses, HSCT significantly improved OS in HSCT candidates, whereas it significantly shortened OS in chemotherapy-only candidates. Integrating KB predictions with ELN 2017 and MRD may thus represent a promising approach to optimize HSCT timing in younger AML patients.
引用
- Fenwarth L, Thomas X, de Botton S, et al. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. Blood. 2021. PMID: 32871585. doi:10.1182/blood.2020005524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。